Salha Bujassoum

Doha, DA, Qatar

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

CLO26-124: Comparative Outcomes of CDK4/6 Inhibitors and Endocrine Therapy in HER2-Low Versus HER2-Negative Metastatic Breast Cancer: A Retrospective Nationwide Cohort Study From Qatar.

CLO26-124: Comparative Outcomes of CDK4/6 Inhibitors and Endocrine Therapy in HER2-Low Versus HER2-Negative Metastatic Breast Cancer: A Retrospective Nationwide Cohort Study From Qatar.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

QIM26-296: Optimizing Chemotherapy Day Care Services Through Workflow Redesign: A Quality Improvement Initiative From Qatar.

QIM26-296: Optimizing Chemotherapy Day Care Services Through Workflow Redesign: A Quality Improvement Initiative From Qatar.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis.

Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis.

Journal: Clinical drug investigation

Published: November 21, 2024

Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study.

Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 28, 2024

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation.

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation.

Journal: Frontiers in oncology

Published: April 07, 2024

QPGx-CARES: Qatar pharmacogenetics clinical applications and research enhancement strategies.

QPGx-CARES: Qatar pharmacogenetics clinical applications and research enhancement strategies.

Journal: Clinical and translational science

Published: February 26, 2024

Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP).

Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP).

Journal: BMC health services research

Published: June 24, 2022

A Grave Outcome of Posterior Reversible Encephalopathy Syndrome in a Patient Receiving Avastin (Bevacizumab) for Metastatic High-Grade Serous Ovarian Cancer.

A Grave Outcome of Posterior Reversible Encephalopathy Syndrome in a Patient Receiving Avastin (Bevacizumab) for Metastatic High-Grade Serous Ovarian Cancer.

Journal: Case reports in oncology

Published: September 10, 2015

Showing 1-8 of 8

Last Updated: 09/26/2026